Arranon (Nelarabine) - Current Clinical Trials

Arranon Related Clinical Trials

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL [Recruiting]

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies [Recruiting]

Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma [Recruiting]

Observational Study of Nelarabine in Children and Young Adults [Recruiting]

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma [Recruiting]

506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) [Recruiting]

506U78 in Treating Patients With Refractory Hematologic Cancer [Active, not recruiting]

506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-Cell Lymphoma [Completed]

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment [Active, not recruiting]

506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia [Active, not recruiting]

506U78 in Treating Patients With Lymphoma [Completed]

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Completed]

506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents [Completed]

506U78 in Treating Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma [Active, not recruiting]

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-Cell Lymphoma [Completed]

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia [Recruiting]